Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 360 entries
View as:

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

Phase: N/A Priority: Normal
NCT ID: NCT01241669 Org: User:
Start: 10/31/10 End: - Due: -

A Study to Evaluate the Food-Effect of H3B-6527

Phase: N/A Priority: Normal
NCT ID: NCT03424577 Org: User:
Start: 12/27/17 End: 01/27/18 Due: 01/27/19

Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

Phase: N/A Priority: Normal
NCT ID: NCT01438840 Org: User:
Start: 02/16/12 End: 03/31/14 Due: 03/31/15

A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT04023877 Org: User:
Start: 07/18/19 End: 10/11/19 Due: 10/11/20

A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Phase: N/A Priority: Normal
NCT ID: NCT01393743 Org: User:
Start: 09/30/11 End: 11/30/15 Due: 11/30/16

An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01975636 Org: User:
Start: 06/30/13 End: 03/31/14 Due: 03/31/15

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

Phase: N/A Priority: Normal
NCT ID: NCT00293176 Org: User:
Start: 12/31/03 End: 03/31/07 Due: 03/31/08

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT00441090 Org: User:
Start: 02/28/07 End: 06/30/09 Due: 06/30/10

A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00499499 Org: User:
Start: 07/31/07 End: 08/31/10 Due: 08/31/11

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01327872 Org: User:
Start: 02/28/11 End: 06/30/11 Due: 06/30/12

E7080 Food Effect Study in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01240408 Org: User:
Start: 07/31/10 End: - Due: -

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)

Phase: N/A Priority: Normal
NCT ID: NCT02513472 Org: User:
Start: 08/28/15 End: 04/06/21 Due: 04/06/22

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Phase: N/A Priority: Normal
NCT ID: NCT00165789 Org: User:
Start: 09/30/05 End: 09/30/06 Due: 09/30/07

A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00869895 Org: User:
Start: 03/31/09 End: - Due: -

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00050960 Org: User:
Start: 05/31/02 End: 03/31/05 Due: 03/31/06

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT02022956 Org: User:
Start: 12/31/13 End: - Due: -

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT06602258 Org: User:
Start: 09/30/24 End: 08/19/27 Due: 08/19/28

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04288089 Org: User:
Start: 04/01/20 End: 03/31/26 Due: 03/31/27

A Study of E2007 In Patients With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00427011 Org: User:
Start: 02/28/07 End: 04/30/08 Due: 04/30/09

Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

Phase: N/A Priority: Normal
NCT ID: NCT00090376 Org: User:
Start: 12/31/03 End: - Due: -

A Study of Subcutaneous Lecanemab in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05045716 Org: User:
Start: 09/07/21 End: 12/07/21 Due: 12/07/22

A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01260155 Org: User:
Start: 01/31/10 End: 06/30/10 Due: 06/30/11

Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00080197 Org: User:
Start: 02/29/04 End: 05/31/05 Due: 05/31/06

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

Phase: N/A Priority: Normal
NCT ID: NCT01321554 Org: User:
Start: 03/17/11 End: 03/19/19 Due: 03/19/20

An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

Phase: N/A Priority: Normal
NCT ID: NCT01146509 Org: User:
Start: 01/31/03 End: 03/31/07 Due: 03/31/08